GRI BIO (NASDAQ: GRI) is a dynamic clinical-stage biotechnology company at the forefront of revolutionizing healthcare through groundbreaking scientific advancements. The company is focused on fundamentally changing how inflammatory, fibrotic and autoimmune diseases are treated.
Category
đź—ž
NewsTranscript
00:00 (upbeat music)
00:02 GRI Bio, trading on the NASDAQ under the ticker GRI,
00:05 is a dynamic and promising clinical stage
00:08 biotechnology company at the forefront
00:10 of revolutionizing healthcare
00:11 through groundbreaking scientific advancements.
00:14 The company is focused on fundamentally changing
00:16 how inflammatory, fibrotic,
00:18 and autoimmune diseases are treated.
00:20 GRI is led by an expert team of executives
00:22 with years of experience
00:23 leading successful biotech companies.
00:26 The combination of business acumen
00:27 and leading scientific research
00:29 makes GRI's efforts to change
00:30 the inflammatory therapy landscape a reality.
00:33 When the body's immune system is working abnormally,
00:36 it can lead to chronic inflammation
00:38 that is extremely damaging.
00:39 Two of the most recognized inflammatory diseases
00:42 are IPF or idiopathic pulmonary fibrosis and lupus.
00:46 IPF and lupus both represent huge markets
00:49 with unmet needs.
00:51 IPF leads of scouring the lungs,
00:53 which makes breathing difficult and painful.
00:55 There are currently no cures and few treatments.
00:58 It was estimated to be a 3.9 billion market in 2022.
01:02 Lupus is an autoimmune disease
01:04 wherein the body essentially attacks itself.
01:06 Like IPF, treatments are limited
01:08 and plagued by side effects.
01:10 The exciting and novel nature of GRI Bio's approach
01:13 and one that could finally bring relief
01:15 to those suffering from IPF and lupus
01:18 centers around NKT cells,
01:20 which are key regulators earlier
01:22 in the inflammatory cascade.
01:23 Specifically, the type one invariant NKT, INKT,
01:27 cells play a critical role in propagating the injury,
01:31 inflammatory response, and fibrosis observed
01:33 in inflammatory and fibrotic indications.
01:36 GRI Bio is focused on developing therapies
01:39 that inhibit INKT cell activity
01:41 to interrupt disease progression
01:43 and restore homeostasis in the immune system.
01:45 The company has a few big years ahead
01:47 with exciting expected milestones,
01:49 some of which are highlighted as follows.
01:52 In the second half of 2023,
01:53 their lead candidate, GRI0621,
01:56 will begin a phase two A biomarker study.
01:59 The data will be announced in 2024.
02:02 In the first half of 2024,
02:03 the IND-enabled studies for GRI0803 will be complete
02:08 and the company will find for IND.
02:11 By the end of 2024,
02:12 results from phase one A and B will be reported.
02:15 These milestones, along with potential of GRI's library
02:18 of over 500 compounds,
02:20 will add to the company's ability
02:21 to fuel a growing pipeline
02:23 and potentially develop new therapies
02:25 for other inflammatory, fibrotic, and autoimmune diseases.
02:29 [MUSIC PLAYING]